January 5, 2016 - Curant Managing Director of Operations, David Cunnold, in Managed Healthcare Executive - The definition of a successful patient journey has evolved since the initial transition to value-based care. The focus on greater healthcare value, a perspective that includes driving better outcomes, necessitates greater patient education on medication therapies and the importance […]
January 4, 2016 – Atlanta, Georgia – One of the nation’s largest independent 340B specialty pharmacies, Curant Health, announces the launch of five new 340B clinic partnerships beginning January 1, 2016: Alivio Medical Center – FQHC (Chicago, IL) Community Health Care Systems, Inc. – FQHC (Wrightsville, GA) Connecticut Children’s Medical Center – Ryan White program […]
Every year, the business of healthcare gathers en mass at the annual J.P. Morgan Healthcare Conference. What will we learn? What will we hear? What will be missing? Sadly, I do not believe we will learn or hear anything of substance, especially when it comes to patient care. This conference is about the healthcare business, […]
January 4, 2016 - Two Curant Health articles made the list of the "2015: Best of Specialty Pharmacy Times Journal." PCSK9 Inhibitors: Smoothing the path to access and value Three things more "presidential" than simply hammering drug manufacturers on price Curant Health is featured in several sections in the Managed Healthcare Executive "Most Popular Pharmacy" […]
December 24, 2015 - Curant COO, Marc O'Connor, featured in Managed Healthcare Executive - One of the biggest aspects of healthcare reform is the shift to value-focused reimbursement, but Marc O’Connor, chief operating officer for Curant Health, a medication management company says it’s not always clear what that entails. Healthcare organizations, he says, should define […]
Curant COO, Marc O’Connor, was recently featured in Specialty Pharmacy Times in a piece that highlights the futility of presidential candidates focusing strictly on pharmaceutical manufacturers as the primary source of healthcare’s woes. It is true that companies such as Turing Pharmaceutical have the ability to cause a strong negative domino effect on patients with pricing […]
December 10, 2015 - Curant COO, Marc O'Connor, in Specialty Pharmacy Times - A case could be made that, overall, health care has not been a focal point of the respective political parties’ presidential nominee debates or campaigns. The discussion has been much, much more specific, focusing on drug manufacturers. In mid-October, both Hillary Clinton […]
Being diagnosed with an illness such as hepatitis C can be shocking for some, to say the least. Receiving a diagnosis of HIV and hepatitis C co-infection can be life-altering. According to the Centers for Disease Control and Prevention (CDC): 25% of patients living with HIV in the U.S. are co-infected with hepatitis C 80% of […]
Hepatitis C is not a new chronic illness, but many people fail to realize how grave the illness is; on some levels, hepatitis C can be compared to HIV in terms of how serious this illness is. There are some interesting and somewhat shocking statistics you may not know about hepatitis C. An estimated 3.2 […]
As 2015 winds down, this would be an opportune time to look at learnings from the last year within the healthcare industry, as well as the future insights from healthcare stakeholders. Curant Health COO, Marc O’Connor, gives his insights on developments providers, manufacturers and payers have seen this year and where future developments will take them […]
